-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cardiovascular disease is caused by heart and vascular diseases, and is a common and frequently-occurring disease
.
At present, it has become one of the diseases that seriously threaten human health in the world today
.
According to new epidemiological data, the prevalence and mortality of cardiovascular diseases in China are still on the rise.
It is estimated that there are about 290 million people suffering from cardiovascular diseases, and deaths from cardiovascular diseases account for more than 40% of the residents’ disease deaths.
It ranks among the top in the total mortality rate of urban and rural residents
.
At present, with the continuous increase of the patient base, the sales of cardiovascular system drugs have also begun to increase year by year
.
It is reported that there are many types of cardiovascular drugs, mainly anti-hypertensive drugs, anti-angina and arrhythmia drugs, anti-heart failure drugs, lipid-lowering drugs, anti-platelet, anti-coagulation drugs, drugs that improve circulation and improve myocardial metabolism
.
In 2019, the sales of cardiovascular system drugs in public hospitals in China reached 126.
31 billion yuan, a year-on-year increase of 2.
2%
.
In the context of the continuous expansion of the entire cardiovascular drug market, more and more domestic pharmaceutical companies are also accelerating their entry into this field
.
For example, recently, the CDE website showed that the esmolol hydrochloride and sodium chloride injection produced by Shanghai Haini Pharmaceuticals of Yangtze River Pharmaceutical Group was accepted by CDE for its imitation of 4 categories
.
It is understood that esmolol hydrochloride is a selective β1 adrenergic receptor blocker, which mainly inhibits β1 receptors by competing for catecholamine binding sites, which can slow down resting and exercise heart rate, lower blood pressure and reduce myocardial oxygen consumption And so on
.
It is clinically used to treat supraventricular tachycardia or uncompensated sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension
.
According to statistics, in 2018, the sales volume of esmolol injection in China's public medical institutions exceeded 500 million yuan, and in 2020 it reached a new high, exceeding 700 million yuan, a year-on-year increase of 24.
75%
.
Among them, it is worth noting that Qilu Pharmaceutical has a relatively large share of this market, exceeding 90%
.
The reason why Qilu Pharmaceutical can occupy the main market is that the industry analysis believes that the main reason is that esmolol hydrochloride injection has the characteristics of fast onset and short action time, and it has a wide range of clinical use and large dosage.
.
Therefore, after Qilu Pharmaceutical’s esmolol hydrochloride injection was launched in China in 2006, after more than ten years of clinical use, it has been widely recognized by doctors and patients for its reliable efficacy and safety, and it has also gained Huge market
.
It is worth mentioning that in 2017, Qilu Pharmaceutical quickly started the consistency evaluation of the product
.
In August of this year, Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved by the State Drug Administration
.
In this regard, the industry believes that under the background of Qilu Pharmaceutical’s continuous deepening of the esmolol sodium chloride injection market, with Qilu Pharmaceutical’s Yangzijiang Esmolol Hydrochloride Sodium Chloride Injection, it is reported to be produced in 4 types of imitations.
Accepted by CDE, the cardiovascular injection market of over 700 million yuan may usher in new changes in the future, and Qilu will also usher in a rival
.
.
At present, it has become one of the diseases that seriously threaten human health in the world today
.
According to new epidemiological data, the prevalence and mortality of cardiovascular diseases in China are still on the rise.
It is estimated that there are about 290 million people suffering from cardiovascular diseases, and deaths from cardiovascular diseases account for more than 40% of the residents’ disease deaths.
It ranks among the top in the total mortality rate of urban and rural residents
.
At present, with the continuous increase of the patient base, the sales of cardiovascular system drugs have also begun to increase year by year
.
It is reported that there are many types of cardiovascular drugs, mainly anti-hypertensive drugs, anti-angina and arrhythmia drugs, anti-heart failure drugs, lipid-lowering drugs, anti-platelet, anti-coagulation drugs, drugs that improve circulation and improve myocardial metabolism
.
In 2019, the sales of cardiovascular system drugs in public hospitals in China reached 126.
31 billion yuan, a year-on-year increase of 2.
2%
.
In the context of the continuous expansion of the entire cardiovascular drug market, more and more domestic pharmaceutical companies are also accelerating their entry into this field
.
For example, recently, the CDE website showed that the esmolol hydrochloride and sodium chloride injection produced by Shanghai Haini Pharmaceuticals of Yangtze River Pharmaceutical Group was accepted by CDE for its imitation of 4 categories
.
It is understood that esmolol hydrochloride is a selective β1 adrenergic receptor blocker, which mainly inhibits β1 receptors by competing for catecholamine binding sites, which can slow down resting and exercise heart rate, lower blood pressure and reduce myocardial oxygen consumption And so on
.
It is clinically used to treat supraventricular tachycardia or uncompensated sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension
.
According to statistics, in 2018, the sales volume of esmolol injection in China's public medical institutions exceeded 500 million yuan, and in 2020 it reached a new high, exceeding 700 million yuan, a year-on-year increase of 24.
75%
.
Among them, it is worth noting that Qilu Pharmaceutical has a relatively large share of this market, exceeding 90%
.
The reason why Qilu Pharmaceutical can occupy the main market is that the industry analysis believes that the main reason is that esmolol hydrochloride injection has the characteristics of fast onset and short action time, and it has a wide range of clinical use and large dosage.
.
Therefore, after Qilu Pharmaceutical’s esmolol hydrochloride injection was launched in China in 2006, after more than ten years of clinical use, it has been widely recognized by doctors and patients for its reliable efficacy and safety, and it has also gained Huge market
.
It is worth mentioning that in 2017, Qilu Pharmaceutical quickly started the consistency evaluation of the product
.
In August of this year, Qilu Pharmaceutical's supplementary application for consistency evaluation of esmolol hydrochloride injection was approved by the State Drug Administration
.
In this regard, the industry believes that under the background of Qilu Pharmaceutical’s continuous deepening of the esmolol sodium chloride injection market, with Qilu Pharmaceutical’s Yangzijiang Esmolol Hydrochloride Sodium Chloride Injection, it is reported to be produced in 4 types of imitations.
Accepted by CDE, the cardiovascular injection market of over 700 million yuan may usher in new changes in the future, and Qilu will also usher in a rival
.
